Drugs / anti-CD5 CAR T cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04594135 | Dec 2020 → Nov 2023 | T-cell acute lymphoblastic leukemia, T-cell non-Hodgkin lymphoma | iCell Gene Therapeutics | Unknown | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | anti-CD5 CAR T cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04594135 ↗ |
| Modality | Cell therapy | “anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells” NCT04594135 ↗ |
| Target | CD5 | “anti-CD5 CAR T cells transduced with a lentiviral vector to express CD5 chimeric receptor domain on T cells” NCT04594135 ↗ |